Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
0
Authors
Roy Fleischmann
Roy Fleischmann•Sebastian Meerwein•Andrea Rubbert‐Roth
